Saturday 17 October 2026 Export JNJ’s income statement to Excel — free account

Johnson & Johnson

JNJ Healthcare Drug Manufacturers General

Johnson & Johnson’s revenue for fiscal 2025 (year ended December 2025) was $94.2 billion, up 6.05% from fiscal 2024. In the quarter to September 2026, revenue grew 5.86%, EPS was flat, free cash flow grew 154.8% and total debt fell 4.82%, each against the same quarter a year earlier. Member of the S&P 500 and Dow Jones; dividend growth for twenty-five consecutive years, revenue growth for three, operating cash flow growth for three; insiders bought in the last twelve months.

255.55 2.27 +0.90%

Follow JNJ

Alert me

Market cap: $610.4B
P/E: 29.6×
Fwd P/E: 24.9×
Dividend yield: 2.07%
F-score: 3/9
Altman Z: 4.78
Beneish M: −2.26
Dividend safety: 78/100

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Insider Decisions trades per month

Total buys 0.26

Total sells 150.67

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	1	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	1	7	—	—	—	1	1	4	1	—

Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 610,380.00

Revenue 99,335.00

Net Income 21,037.00

Free Cash Flow 22,724.00

Net Debt 16,586.00

Current Ratio 1.09

Debt/Equity 0.44

P/E ratio 29.61

Fwd P/E 24.90

P/S ratio 6.19

P/B ratio 7.24

Past 5Y EPS Growth 14.89%

This Y EPS Growth 3.43%

Next Y EPS Growth 5.87%

Next Y revenue growth 7.67%

Next 5Y EPS Growth 9.11%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/E against its own 10 years 82.57%

10-year low 10-year high

P/S against its own 10 years 96.76%

10-year low 10-year high

P/B against its own 10 years 97.31%

10-year low 10-year high

EV/Sales against its own 10 years 96.65%

10-year low 10-year high

EV/FCF against its own 10 years 91.74%

10-year low 10-year high

Dividends

Payout Ratio 0.80

Annual Dividend Rate 5.28

Annual Dividend Yield 2.07%

	total	individual payouts
2028	Powerpack
2027	Powerpack
2026	5.34	1.30 1.34 1.34
2025	5.14	1.24 1.30 1.30 1.30
2024	4.91	1.19 1.24 1.24 1.24
2023	4.70	1.13 1.19 1.19 1.19
2022	4.45	1.06 1.13 1.13 1.13
2021	4.19	1.01 1.06 1.06 1.06
2020	3.98	0.95 1.01 1.01 1.01
2019	3.75	0.90 0.95 0.95 0.95
2018	3.54	0.84 0.90 0.90 0.90
2017	3.32	0.80 0.84 0.84 0.84
2016	3.15	0.75 0.80 0.80 0.80

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	22,927	24,522	20,102	20,758
Receivables	14,873	14,842	17,178	19,046
Inventory	11,181	12,444	14,191	15,144
Other	—	—	—	—
	53,495	55,893	55,624	59,774

	2023	2024	2025	Q'26
Payables	9,632	10,311	11,991	9,223
ST’ Debt	—	—	—	—
Other	—	—	—	—
	46,282	50,321	54,126	54,895

Compound Annual Growth %

	10y	5y	3y
Sales	3.00%	2.67%	5.60%
Cash Flow	2.29%	0.83%	4.99%
Earnings	5.69%	12.74%	14.32%
Book Value	1.37%	5.20%	2.02%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	24,062	25,310	25,399	—	—
’25	21,893	23,743	23,993	24,564	94,193
’24	21,383	22,447	22,471	22,520	88,821
’23	20,894	21,519	21,351	21,395	85,159
’22	23,426	24,020	19,996	12,548	79,990
’21	22,321	23,312	23,338	9,769	78,740
’20	20,691	18,336	21,082	22,475	82,584

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	2,514	8,616	—	—	—
’25	4,174	3,878	9,169	7,309	24,530
’24	3,657	5,633	7,993	6,983	24,266
’23	3,257	4,182	7,489	7,863	22,791
’22	3,979	5,581	6,284	5,350	21,194
’21	4,074	5,314	8,290	5,732	23,410
’20	3,358	3,452	8,383	8,343	23,536

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	1,494	7,358	—	—	—
’25	3,658	2,888	8,088	5,784	20,418
’24	3,060	5,020	7,014	5,423	20,517
’23	2,434	3,134	6,643	6,395	18,606
’22	3,620	4,784	5,340	3,984	17,728
’21	4,000	4,552	7,555	4,362	20,469
’20	2,750	2,860	7,659	7,225	20,494

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	2.14	2.27	0.09	—	—
’25	4.54	2.29	2.12	2.10	11.03
’24	1.34	1.93	1.11	1.41	5.79
’23	(0.03)	1.96	10.21	1.67	13.72
’22	1.93	1.80	1.68	1.33	6.73
’21	2.32	2.35	1.37	1.77	7.81
’20	2.17	1.36	1.33	0.65	5.51

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	94.28	110.76	118.62	125.00	109.16	151.47	155.72	144.95	142.75	140.68	Analyst estimates 2026–2028 Powerpack
	High	126.07	144.35	148.99	147.84	157.66	179.92	186.69	180.93	168.85	215.19
People
People	Employees	126,400	134,000	135,100	132,200	134,500	141,700	155,800	131,900	138,100	138,200
	Revenue/emp, $m	0.57	0.57	0.60	0.62	0.61	0.56	0.51	0.65	0.64	0.68
Income, $m
Income, $m	Revenue	71,890	76,450	81,581	82,059	82,584	78,740	79,990	85,159	88,821	94,193
	Gross margin, %	69.69	66.72	66.79	66.42	65.58	70.28	69.25	68.82	69.07	67.88
	EBT	19,803	17,673	17,999	17,328	16,497	19,178	19,359	15,062	16,687	32,581
	EBT margin, %	27.55	23.12	22.06	21.12	19.98	24.36	24.20	17.69	18.79	34.59
	Net income	16,540	1,300	15,297	15,119	14,714	20,878	17,941	35,153	14,066	26,804
	Depreciation	3,754	5,642	6,929	7,009	7,231	7,390	6,970	7,486	7,339	7,503
Per share, $
Per share, $	Revenue	26.26	28.40	30.42	31.02	31.37	29.92	30.47	33.61	36.90	39.13
	Earnings	5.93	0.47	5.61	5.63	5.51	7.81	6.73	13.72	5.79	11.03
	Cash flow	6.86	7.82	8.28	8.85	8.94	8.89	8.07	9.00	10.08	10.19
	Capex	(0.72)	(0.54)	(0.17)	(0.09)	(1.16)	(1.12)	(1.32)	(1.65)	(1.56)	(1.71)
	Free cash flow	6.14	7.28	8.11	8.76	7.78	7.78	6.75	7.34	8.52	8.48
	Book value	25.73	22.35	22.28	22.48	24.03	28.12	29.26	27.15	29.70	33.87
	Shares, m	2,737	2,692	2,682	2,645	2,633	2,632	2,625	2,534	2,407	2,407
Valuation, ×
Valuation, ×	P/E	19.70	357.00	23.00	25.89	28.56	21.90	26.44	11.58	24.93	18.73
	P/S	4.41	4.90	4.24	4.70	5.02	5.72	5.85	4.76	3.92	5.29
	P/B	4.36	6.23	5.79	6.49	6.55	6.08	6.09	5.89	4.87	6.11
	EV/Sales	4.14	5.06	4.34	4.79	5.11	5.70	5.91	4.79	3.99	5.49
	EV/FCF	17.71	19.75	16.29	16.95	20.58	21.92	26.65	21.94	17.27	25.35
Cash, $m
Cash, $m	Operating cash flow	18,767	21,056	22,201	23,416	23,536	23,410	21,194	22,791	24,266	24,530
	Capex	(1,959)	(1,447)	(467)	(233)	(3,042)	(2,941)	(3,466)	(4,185)	(3,749)	(4,112)
	Free cash flow	16,808	19,609	21,734	23,183	20,494	20,469	17,728	18,606	20,517	20,418
Balance, $m
Balance, $m	Working capital	38,745	12,551	14,803	9,310	8,744	15,753	(508)	7,213	5,572	1,498
	Total debt	22,442	30,675	27,684	26,494	32,635	29,985	26,886	25,881	30,651	39,438
	Net debt	(19,465)	12,379	7,997	7,207	7,450	(1,623)	4,605	2,954	6,129	19,336
	Shareholders’ equity	70,418	60,160	59,752	59,471	63,278	74,023	76,804	68,774	71,490	81,544
Returns, %
Returns, %	ROA	12.05	0.87	9.86	9.73	8.85	11.70	9.71	19.81	8.09	14.13
	ROIC	24.29	15.23	16.60	16.24	14.58	16.56	14.86	13.12	13.44	20.19
	ROE	23.60	1.99	25.51	25.36	23.97	30.41	23.79	48.29	20.06	35.03

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 14 Oct 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
LLY Eli Lilly and Company	$1.18T	42.2×	33.1×	+47.67% (above 0%: growing)	+26.23% (above 0%: growing)	+458.06% (above 0%: growing)	85.78%	39.08%	Compare
JNJ Johnson & Johnson	$610.4B	29.6×	24.9×	+5.86% (above 0%: growing)	−0.87% (below 0%: shrinking)	+154.78% (above 0%: growing)	68.12%	0.01%
ABBV AbbVie Inc.	$500.8B	80.6×	27.8×	+10.16% (above 0%: growing)	+290.38% (above 0%: growing)	−36.24% (below 0%: shrinking)	74.74%	37.86%	Compare
MRK Merck & Co., Inc.	$358.2B	117×	53.9×	+5.07% (above 0%: growing)	n/m	+77.03% (above 0%: growing)	73.54%	(2.61%)	Compare
NVS Novartis AG	$275.3B	22.6×	20.6×	+0.78% (above 0%: growing)	−17.39% (below 0%: shrinking)	−15.53% (below 0%: shrinking)	75.19%	31.77%	Compare
AZN AstraZeneca PLC	$258.5B	24.5×	23.4×	+6.41% (above 0%: growing)	+1.90% (above 0%: growing)	−107.45% (below 0%: shrinking)	83.60%	20.57%	Compare
AMGN Amgen Inc.	$234.7B	26.7×	22.7×	+9.53% (above 0%: growing)	+65.41% (above 0%: growing)	+82.57% (above 0%: growing)	72.04%	34.95%	Compare
GILD Gilead Sciences, Inc.	$195.1B	— (loss-making)	— (loss-making)	+10.18% (above 0%: growing)	n/m	+376.81% (above 0%: growing)	79.76%	(133.21%)	Compare
PFE Pfizer Inc.	$167.8B	38.9×	12.2×	+2.60% (above 0%: growing)	n/m	+125.17% (above 0%: growing)	72.78%	20.38%	Compare
Median of peers	$266.9B	38.9×	23.4×	+7.97%	+26.23%	+79.80%	74.96%	26.17%

All 21 Drug Manufacturers General stocks →

Johnson & Johnson (JNJ) key facts

Strength: Johnson & Johnson’s revenue for fiscal 2025 (year ended December 2025) was $94.2 billion, up 6.05% from fiscal 2024.
Johnson & Johnson (JNJ) is a Drug Manufacturers General company in the Healthcare sector, listed on the New York Stock Exchange.
As of October 16, 2026, JNJ traded at $255.55, a market capitalization of $610.4 billion.
Johnson & Johnson pays an annual dividend of $5.28 per share, a yield of 2.07%, with a payout ratio of 80.1%.
Return on equity was 35.0% and debt-to-equity 0.44.
Its Piotroski F-score is 3 out of 9 and its Altman Z-score is 4.78 (safe zone) for fiscal 2025.